OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Martin on Selinexor in Triple-Class Refractory Multiple Myeloma

January 25th 2020

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

Dr. Sartor on Promising Treatment Approaches in Prostate Cancer

January 25th 2020

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

Genomic Sequencing and Identifying Driver Mutations in AML and MDS

January 25th 2020

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Dr. Tolaney on the Advantages of ctDNA Versus Tissue Biopsy in Breast Cancer

January 25th 2020

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Dr. Penson on Questions Regarding Next-Generation AR Inhibitors in Prostate Cancer

January 25th 2020

David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.

Dr. Kohli on Drugs That Have Been Evaluated in mCRPC

January 25th 2020

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Dr. Cosgrove on the Approval of Niraparib in Advanced Ovarian Cancer

January 24th 2020

Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

January 24th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Dr. Hwang on Treatment Selection in Metastatic Castration-Sensitive Prostate Cancer

January 24th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLL

January 24th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Paulson on Molecular Testing in Oncology

January 24th 2020

R. Steven Paulson, MD, discusses molecular testing in oncology.

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin Lymphoma

January 24th 2020

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Dr. Brammer on the Transformation of Stem Cell Transplant in ALL

January 24th 2020

Jonathan E. Brammer, MD, discusses the progression of transplant in acute lymphoblastic leukemia.

Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLC

January 24th 2020

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

January 24th 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Dr. Cline on Data With PARP Inhibitors in Pancreatic Cancer

January 23rd 2020

Mika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.

Dr. Voorhees on Updated Depth of Response in GRIFFIN Trial in Multiple Myeloma

January 23rd 2020

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Dr. Hegazi on Nutrition-Related Toxicities in Oncology

January 23rd 2020

Refaat Hegazi, MD, PhD, MPH, discusses nutrition-related toxicities in oncology.

Dr. Vusirikala on the Role of MRD in ALL

January 23rd 2020

Madhuri Vusirikala, MD, discusses the role of minimal residual disease in acute lymphoblastic leukemia.

Dr. Heath on Remaining Challenges in Nonmetastatic CRPC

January 23rd 2020

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.